Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 6 Ovarian Neoplasms 4 Neoplasms 3 Endometrial Neoplasms 3 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Bulbo-Spinal Atrophy, X-Linked 1 Biliary Tract Neoplasms 1 Advanced Breast Cancer 1 Adenocarcinoma of Lung 1

Interventions

Fulvestrant 13 Letrozole 6 Anastrozole 5 palbociclib 4 exemestane 3 Injections 3 Docetaxel 3 Paclitaxel 2 Goserelin 2 Dasatinib 2 Capecitabine 2 Alpelisib 2 AZD9833 2 vandetanib 1 ribociclib 1 irinotecan sucrosofate 1 entinostat 1 elacestrant 1 cediranib 1 abemaciclib 1 XMT-1522 1 Vinorelbine 1 Sirolimus 1 Ritonavir 1 Lead 1 Itraconazole 1 Immunotherapy, Adoptive 1 Everolimus 1 Decitabine 1 Combined Modality Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Breast Cancer × AZD5305 × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡